Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TTBCF
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
39837982 ADC PCMdt-MMAE
|
|||||
| Synonyms |
ADC PCMdt-MMAE
Click to Show/Hide
|
|||||
| Organization |
Zhejiang University School of Medicine.; Texas Tech University Health Sciences Center.; Ningbo University.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
PCMbs-MR
|
Antibody Info | ||||
| Antigen Name |
Hepatocyte growth factor receptor (MET); Macrophage-stimulating protein receptor (MST1R)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Site-specific bioconjugation via AJICAP-M at K248.
|
|||||
| Combination Type |
Vedotin
|
|||||
General Information of The ADMET Data Related to This ADC(2027 Update)
Absorption
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) | 76.67±8.84 | ug/mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice with xenograft tumors, 3mg/kg.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 332.77±38.91 | day*ug/mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice with xenograft tumors, 3mg/kg.
|
[1] |
| Maximum Observed Concentration (Cmax) | 241.6±19.92 | ug/mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice with xenograft tumors, 10 mg/kg.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1602.29±102.15 | day*ug/mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice with xenograft tumors, 10 mg/kg.
|
[1] |
| Maximum Observed Concentration (Cmax) | 82.18±9.33 | ug/mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice without xenograft tumors, 3mg/kg.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 357.28±41.25 | day*ug/mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice without xenograft tumors, 3mg/kg.
|
[1] |
| Maximum Observed Concentration (Cmax) | 226.51±24.81 | ug/mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice without xenograft tumors, 10 mg/kg.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1639.46±146.78 | day*ug/mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice without xenograft tumors, 10 mg/kg.
|
[1] |
Distribution
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Volume of Distribution (Vd) | 0.94±0.27 | mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice with xenograft tumors, 3mg/kg, central compartment volume.
|
[1] |
| Volume of Distribution (Vd) | 1.34±0.28 | mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice with xenograft tumors, 3mg/kg, steady state volume.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 332.77±38.91 | day*ug/mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice with xenograft tumors, 3mg/kg.
|
[1] |
| Volume of Distribution (Vd) | 0.998±0.35 | mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice with xenograft tumors, 10 mg/kg, central compartment volume.
|
[1] |
| Volume of Distribution (Vd) | 1.51±0.16 | mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice with xenograft tumors, 10 mg/kg, steady state volume.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1602.29±102.15 | day*ug/mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice with xenograft tumors, 10 mg/kg.
|
[1] |
| Volume of Distribution (Vd) | 1.05±0.28 | mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice without xenograft tumors, 3mg/kg, central compartment volume.
|
[1] |
| Volume of Distribution (Vd) | 1.57±0.17 | mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice without xenograft tumors, 3mg/kg, steady state volume.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 357.28±41.25 | day*ug/mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice without xenograft tumors, 3mg/kg.
|
[1] |
| Volume of Distribution (Vd) | 0.94±0.21 | mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice without xenograft tumors, 10 mg/kg, central compartment volume.
|
[1] |
| Volume of Distribution (Vd) | 1.44±0.22 | mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice without xenograft tumors, 10 mg/kg, steady state volume.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1639.46±146.78 | day*ug/mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice without xenograft tumors, 10 mg/kg.
|
[1] |
Metabolism
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Area Under the Concentration-Time Curve (AUC) | 332.77±38.91 | day*ug/mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice with xenograft tumors, 3mg/kg.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1602.29±102.15 | day*ug/mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice with xenograft tumors, 10 mg/kg.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 357.28±41.25 | day*ug/mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice without xenograft tumors, 3mg/kg.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1639.46±146.78 | day*ug/mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice without xenograft tumors, 10 mg/kg.
|
[1] |
Excretion
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Clearance (CL) | 0.19±0.02 | mL/day/kg |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice with xenograft tumors, 3mg/kg.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 332.77±38.91 | day*ug/mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice with xenograft tumors, 3mg/kg.
|
[1] |
| Elimination Half-Life (t1/2) | 6.05±0.37 | day |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice with xenograft tumors, 3mg/kg.
|
[1] |
| Clearance (CL) | 0.2±0.06 | mL/day/kg |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice with xenograft tumors, 10 mg/kg.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1602.29±102.15 | day*ug/mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice with xenograft tumors, 10 mg/kg.
|
[1] |
| Elimination Half-Life (t1/2) | 6.61±0.26 | day |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice with xenograft tumors, 10 mg/kg.
|
[1] |
| Clearance (CL) | 0.23±0.04 | mL/day/kg |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice without xenograft tumors, 3mg/kg.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 357.28±41.25 | day*ug/mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice without xenograft tumors, 3mg/kg.
|
[1] |
| Elimination Half-Life (t1/2) | 6.12±0.14 | day |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice without xenograft tumors, 3mg/kg.
|
[1] |
| Clearance (CL) | 0.18±0.03 | mL/day/kg |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice without xenograft tumors, 10 mg/kg.
|
[1] |
| Area Under the Concentration-Time Curve (AUC) | 1639.46±146.78 | day*ug/mL |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice without xenograft tumors, 10 mg/kg.
|
[1] |
| Elimination Half-Life (t1/2) | 6.26±0.37 | day |
Pharmacokinetic profiles and toxic activities of PCMdt-MMAE in mice without xenograft tumors, 10 mg/kg.
|
[1] |
References